Graves Ophthalmopathy: all 198 studies
Page 2 of 2. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseActive, not recruitingNCT06401044Phase 1/2
- A Study of TEPEZZA® Treatment in Participants With Thyroid Eye DiseaseCompletedNCT06389578Phase 1
- Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)CompletedNCT06367517
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.TerminatedNCT06307626Phase 3
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye DiseaseTerminatedNCT06307613Phase 3
- A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated OphthalmopathyCompletedNCT06269393Phase 3
- A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye DiseaseActive, not recruitingNCT06248619Phase 3
- A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseaseCompletedNCT06126783Phase 3
- A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseActive, not recruitingNCT06088979Phase 2
- Efficacy and Safety of Tocilizumab for TAOWithdrawnNCT06087731Phase 2
- A Study of IBI311 in Subjects With Active Thyroid Eye DiseaseCompletedNCT05795621Phase 2/3
- Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' OrbitopathyCompletedNCT05793359
- Study of ZB001 in Chinese Patients With Thyroid Eye DiseaseCompletedNCT05776121Phase 1
- Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' OrbitopathyCompletedNCT05775185
- Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid DysfunctionCompletedNCT05731154
- Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)CompletedNCT05683496Phase 1/2
- Exploring Immunological Markers Associated With Mental Fatigue in Graves' DiseaseTerminatedNCT05678374
- Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's OphthalmopathyStatus unknownNCT05627401
- Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.Status unknownNCT05532072Early Phase 1
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseCompletedNCT05524571Phase 3
- Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseaseTerminatedNCT05517447Phase 3
- Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseaseCompletedNCT05517421Phase 3
- Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular InjectionsCompletedNCT05429450Phase 2
- Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy PatientsTerminatedNCT05394857Phase 2
- Sirolimus in Graves' OrbitopathyCompletedNCT05345119
- A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye DiseaseCompletedNCT05331300Phase 1/2
- AS-OCT of the Cornea in Thyroid DiseasesStatus unknownNCT05241626
- Antithymocyte Globulin as a Second Line Therapy in Graves OrbitopathyStatus unknownNCT05199103Not applicable
- A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye DiseaseStatus unknownNCT05015127Phase 2/3
- TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement StudyCompletedNCT05002998Phase 4
- Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye DiseaseCompletedNCT04976816Phase 2/3
- Supramaximal Rectus Recession for Strabismus in Grave's OphthalmopathyStatus unknownNCT04927468Not applicable
- Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated OphthalmopathyStatus unknownNCT04919694Not applicable
- Tocilizumab in Active Moderate-severe Graves' OrbitopathyCompletedNCT04876534Phase 2
- Exophthalmometry With 3D Face ScannersStatus unknownNCT04704414Not applicable
- Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery.CompletedNCT04662190Not applicable
- Immunological Follow-up of Patients With Basedow's OrbitopathyCompletedNCT04610723
- Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAOStatus unknownNCT04548284Phase 3
- Genetics and Epigenetics of Graves' OrbitopathyCompletedNCT04488406
- Corneal Tomographic Parameters in TGDCompletedNCT04433936
- Heart Rhythm After Intravenous Methylprednisolone AdministrationCompletedNCT04391439
- Tamsulosin for Thyroid Lid RetractionStatus unknownNCT04359979Not applicable
- The Therapeutic Effect of Dysthyroid Optic NeuropathyStatus unknownNCT04096612Not applicable
- Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye DiseaseApproved for marketingNCT04040894
- Deep Lateral Wall Partial Rim-Sparing Orbital Decompression for Treatment of Thyroid-Related OrbitopathyCompletedNCT04025034Not applicable
- 99Tc-MDP for Thyroid-Associated OphthalmopathyCompletedNCT03948191Phase 4
- Oral Supplementation With Selenium in Patients With Mild Thyroid OrbitopathyCompletedNCT03891043Not applicable
- Liver Function After Intravenous Methylprednisolone AdministrationCompletedNCT03667157Phase 4
- Impact of Intravenous Methylprednisolone Treatment on Blood PressureCompletedNCT03590080
- Coagulation After Intravenous Methylprednisolone AdministrationCompletedNCT03535090
- Natural History and Risk Factors of TAOStatus unknownNCT03515863
- Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' OrbitopathyCompletedNCT03498417
- Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye DiseaseStatus unknownNCT03324022
- Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves OrbitopathyCompletedNCT03278964Not applicable
- T and B Cells in Graves' OrbitopathyCompletedNCT03195296
- Effects of Atorvastatin in Graves' Orbitopathy (GO)CompletedNCT03110848Phase 2
- Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior TrialStatus unknownNCT03107078Phase 4
- Disappearance of Graves' OrbitopathyCompletedNCT03103607
- Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' OphthalmopathyStatus unknownNCT03066076Phase 3
- Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated OphthalmopathyCompletedNCT02766660Not applicable
- Graves' Orbitopathy and HypercholesterolemiaCompletedNCT02721992
- New Treatment for Patients With Temporal Hollowing After Lateral Wall DecompressionCompletedNCT02693808Not applicable
- The Effects of Metformin in Patients With Mild Graves' OphthalmopathyStatus unknownNCT02535975Not applicable
- The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye DiseaseWithdrawnNCT02422368Phase 2/3
- mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)CompletedNCT02397109
- The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)WithdrawnNCT02393183Phase 2/3
- Role of the Microbiome in Graves' OrbitopathyStatus unknownNCT02373995Phase 1/2
- Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye DiseaseStatus unknownNCT02339142Phase 4
- B-cell Depletion Therapy With Rituximab for Thyroid Eye DiseaseTerminatedNCT02316691
- Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal PeopleStatus unknownNCT02290704
- Doxycycline Treatment in Mild Thyroid-Associated OphthalmopathyStatus unknownNCT02203682Phase 2
- Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin AnaloguesCompletedNCT02155049Phase 3
- Selenium in Mild Thyroid Eye Disease in North AmericaWithdrawnNCT02112643Phase 3
- Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)CompletedNCT02059655Phase 4
- Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's OrbitopathyStatus unknownNCT01999790Not applicable
- A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' OrbitopathyStatus unknownNCT01969019Phase 4
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.WithdrawnNCT01927406Phase 4
- Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune TreatmentTerminatedNCT01893450Not applicable
- Prednisone Versus Doxycycline in the Treatment of Graves' OrbitopathyStatus unknownNCT01809444Phase 2/3
- Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye DiseaseTerminatedNCT01738243Phase 4
- Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' OrbitopathyCompletedNCT01727973Phase 1/2
- Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone InjectionsCompletedNCT01599273Phase 4
- The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated OphthalmopathyCompletedNCT01579539Phase 3
- Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)CompletedNCT01458600Phase 4
- Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s OrbitopathyWithdrawnNCT01379196Phase 1/2
- Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)CompletedNCT01297699Phase 3
- Local Triamcinolone Injection in Active Thyroid OrbitopathyStatus unknownNCT01280214Not applicable
- Use of Botox in the Management of Thyroid Related Upper Eyelid RetractionWithdrawnNCT01272414Phase 4
- The Effect of Early Total Thyroidectomy in the Course of Graves' OrbitopathyStatus unknownNCT01056419Phase 4
- Color Doppler Imaging of Orbital Venous Flow in Grave's OrbitopathyCompletedNCT00697528
- Morphometric Analysis of Orbital Structures in Graves´ OrbitopathyCompletedNCT00665795
- Thyroid-Associated Ophthalmopathy Subtypes and Orbital AntibodiesCompletedNCT00430547Not applicable
- Rituximab Treatment of Graves' Dysthyroid OphthalmopathyCompletedNCT00424151Phase 1/2
- Thyroid Treatment TrialCompletedNCT00348413Not applicable
- Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy TreatmentTerminatedNCT00288522Phase 2
- The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'OphthalmopathyStatus unknownNCT00174057
- Rituximab in the Treatment of Graves' DiseaseCompletedNCT00150111Phase 1/2
- Randomized Study of Sequential Orbital Radiotherapy for Graves' OphthalmopathyCompletedNCT00004660Not applicable